注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Astria Therapeutics Inc是一家生物製藥公司,專注於發現、開發和商業化治療受罕見和特殊過敏性和免疫性疾病影響的患者和家庭。該公司的主要候選產品是STAR-0215,其為一種潛在的血漿激肽釋放酶單克隆抗體抑製劑,用於治療遺傳性血管水腫(HAE)。遺傳性血管水腫是一種罕見的遺傳性疾病,其特徵是面部、四肢、腹部和氣道出現嚴重、復發、不可預測、疼痛,有時甚至危及生命的腫脹。STAR-0215是血漿激肽釋放酶的單克隆抗體抑製劑,旨在為遺傳性血管水腫提供長效預防。該公司的遺傳性血管水腫治療按需治療包括BERINERT、Firazr、KALBITOR和RUCONEST。其遺傳性血管水腫治療的長期預防性治療包括CINRYZE、HAEGARDA、TAKHZYRO和ORLADEYO。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Kenneth M. Bate | 73 | 2014 | Independent Chairman of the Board |
Jill C. Milne | 55 | 2008 | Co-Founder, CEO, President & Director |
Jonathan Violin | 48 | 2021 | Independent Director |
Hugh M. Cole | 58 | 2019 | Independent Director |
Frederick Peter Callori | 55 | 2021 | Independent Director |
Gregory Anthony Lapointe | 64 | 2019 | Independent Director |
Jay D. Horton | - | - | Member of Scientific Advisory Board |
Joanne T. Beck | 61 | 2019 | Independent Director |
Johannes Jacob Pieter Kastelein | 69 | - | Member of Scientific Advisory Board |
Steven E. Shoelson | - | - | Member of Scientific Advisory Board |
Roger Ulrich | - | - | Member of Scientific Advisory Board |
Michael Jirousek | 64 | 2008 | Member of Scientific Advisory Board |
Sekar Kathiresan | 51 | - | Member of Scientific Advisory Board |
Edward M. Scolnick | 82 | - | Member of Scientific Advisory Board |
Michael D. Kishbauch | 74 | 2016 | Independent Director |
Arthur H. Rubenstein | 86 | - | Member of Scientific Advisory Board |
Sunil Agarwal | 54 | 2024 | Independent Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核